Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28956491 | 1.00 | ALDH1A1 (0.43) | ALDH1A1HTR1ADRD2HTR2ALMNA | |
| SCHEMBL9085541 | 0.96 | HTR1A (0.40) | ALDH1A1HTR1ADRD2HTR2ALMNA | |
| SCHEMBL9437810 | 0.90 | ALDH1A1 (0.41) | ALDH1A1HTR1ADRD2HTR2ALMNA | |
| SCHEMBL10948563 | 0.88 | ALDH1A1 (0.49) | ALDH1A1HTR1ADRD2HTR2ALMNA | |
| SCHEMBL17532423 | 0.88 | ALDH1A1 (0.49) | ALDH1A1HTR1ADRD2HTR2ALMNA | |
| SCHEMBL17532416 | 0.86 | ALDH1A1 (0.50) | ALDH1A1HTR1ADRD2HTR2ALMNA | |
| SCHEMBL17532412 | 0.81 | ALDH1A1 (0.53) | ALDH1A1KMT2ARAB9AHTTSMN1; SMN2 | |
| SCHEMBL9119239 | 0.81 | ALDH1A1 (0.43) | ALDH1A1HTR1ADRD2HTR2ALMNA | |
| SCHEMBL14359600 | 0.81 | ALDH1A1 (0.47) | ALDH1A1HTR1ADRD2HTR2ALMNA | |
| SCHEMBL11845960 | 0.81 | CNR2 (0.46) | ALDH1A1HTR1ALMNACHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383913-A1 | THIOPHENE RING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2024-11-21 | — | — | US | disclosed |
| CN-115873005-A | Preparation and purification method and application of high-purity perospirone hydrochloride intermediate | 四川科瑞德制药股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-115772175-A | Thieno-ring compounds, process for their preparation and their use | 中国科学院分子细胞科学卓越创新中心 | 2023-03-10 | — | — | CN | disclosed |
| CN-115707701-A | High-purity perospirone and preparation method and application thereof | 四川科瑞德制药股份有限公司 | 2023-02-21 | — | — | CN | disclosed |
| EP-0314098-B1 | IMIDE DERIVATIVES, THEIR PRODUCTION AND USE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1993-08-04 | — | — | EP | disclosed |
| US-4937249-A | Neuroleptic agents | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-06-26 | — | — | US | disclosed |
| EP-0314098-A2 | Imide derivatives, their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1989-05-03 | — | — | EP | disclosed |
| EP-0109562-B1 | SUCCINIMIDE DERIVATIVES AND THEIR PRODUCTION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-09-02 | — | — | EP | disclosed |
| US-4598078-A | N-(substituted piperazinyl) alkylbicyclic succinimide derivatives | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-07-01 | — | — | US | disclosed |
| EP-0109562-A1 | Succinimide derivatives and their production | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383913-A1 | THIOPHENE RING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TACR1, HTR1F, TPH1 | ALDH1A1 687/4885HTR1A 16/4885DRD2 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.